ATE360632T1 - Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate - Google Patents

Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate

Info

Publication number
ATE360632T1
ATE360632T1 AT04804431T AT04804431T ATE360632T1 AT E360632 T1 ATE360632 T1 AT E360632T1 AT 04804431 T AT04804431 T AT 04804431T AT 04804431 T AT04804431 T AT 04804431T AT E360632 T1 ATE360632 T1 AT E360632T1
Authority
AT
Austria
Prior art keywords
cycloalkylamin
dihydrospiro
dinyl
pyrimido
pyri
Prior art date
Application number
AT04804431T
Other languages
English (en)
Inventor
Nathalie Chereze
Alistair Lochead
Mourad Saady
Franck Slowinski
Philippe Yaiche
Original Assignee
Sanofi Aventis
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Mitsubishi Pharma Corp filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE360632T1 publication Critical patent/ATE360632T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/141—Feedstock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04804431T 2003-12-19 2004-12-17 Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate ATE360632T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03293236A EP1557417B1 (de) 2003-12-19 2003-12-19 Substituierte 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one Derivate

Publications (1)

Publication Number Publication Date
ATE360632T1 true ATE360632T1 (de) 2007-05-15

Family

ID=34626443

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04804431T ATE360632T1 (de) 2003-12-19 2004-12-17 Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate

Country Status (28)

Country Link
US (2) US7294631B2 (de)
EP (2) EP1557417B1 (de)
JP (1) JP4896734B2 (de)
KR (1) KR20060127055A (de)
CN (1) CN1914208B (de)
AR (1) AR047056A1 (de)
AT (1) ATE360632T1 (de)
AU (1) AU2004299285B2 (de)
BR (1) BRPI0417208A (de)
CA (1) CA2550168A1 (de)
CY (1) CY1107982T1 (de)
DE (1) DE602004006169T2 (de)
DK (1) DK1699795T3 (de)
EA (1) EA010419B1 (de)
ES (1) ES2286707T3 (de)
HR (1) HRP20070328T3 (de)
IL (1) IL176287A0 (de)
ME (1) MEP21408A (de)
MX (1) MXPA06006931A (de)
NO (1) NO20063187L (de)
NZ (1) NZ547956A (de)
PL (1) PL1699795T3 (de)
PT (1) PT1699795E (de)
RS (1) RS50519B (de)
SI (1) SI1699795T1 (de)
TW (1) TWI346664B (de)
WO (1) WO2005058908A1 (de)
ZA (1) ZA200604960B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972342A4 (de) * 2005-07-29 2011-01-12 Univ Barcelona Pharmazeutische zusammensetzungen aus einem wolframsalz (vi) zur behandlung von neurodegenerativen störungen, insbesondere alzheimer-krankheit und schizophrenie
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP1921080B1 (de) * 2006-11-07 2009-08-05 Sanofi-Aventis Subsitituierte Derivate des 8-Piperidinyl-2-pyridinylpyrimido(1,2-a)pyrimidin-6-ons und des 8-Piperidinyl-2-pyrimidinylpyrimido(1,2-a)pyrimidin-6-ons
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2085400A1 (de) 2008-01-29 2009-08-05 Sanofi-Aventis Substituierte Heteroarylamid-Oxazepinopyrimidon-Derivate
EP2090579A1 (de) 2008-01-29 2009-08-19 Sanofi-Aventis Substituierte Heteroarylamiddiazepinopyrimidon-Derivate
EP2090578A1 (de) 2008-01-29 2009-08-19 Sanofi-Aventis Substituierte Arylamid-Diazepinopyrimidon-Derivate zur Behandlung von neurodegenerativen Erkrankungen verursacht durch eine abnormale GSK3-beta-Aktivität
EP2085399A1 (de) 2008-01-29 2009-08-05 Sanofi-Aventis Substituierte Arylamidoxazepinopyrimidon-Derivate
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8446810B2 (en) 2008-10-01 2013-05-21 Panasonic Corporation Information recording medium having recording condition for adjusting the position of cooling pulse
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
BRPI1015943A8 (pt) 2009-07-02 2018-01-09 Sanofi Sa derivados de 1,2,3,4-tetra - hidro - pirimido {1,2-a} pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica.
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
DK2655375T3 (en) 2010-12-23 2015-03-09 Sanofi Sa PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP3592747A1 (de) * 2017-03-10 2020-01-15 Council of Scientific and Industrial Research Spirooxindolverbindungen als gsk3-inhibitoren und verfahren zur herstellung davon
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
CN112694478A (zh) * 2020-12-24 2021-04-23 绍兴文理学院 一种硝基取代含哒嗪酮结构的螺吡唑-吡咯里嗪衍生物及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130181A0 (en) * 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
JP2004507546A (ja) * 2000-09-01 2004-03-11 サノフィ−サンテラボ ２−ピリジニル−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オンおよび７−ピリジニル−２，３−ジヒドロイミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体
EP1295885A1 (de) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituierte 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)onderivate
EP1340761A1 (de) * 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituierte 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on und 7-Pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
EP1340760A1 (de) * 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituierte 2-Pyrimidinyl-6,7,8,9-tetrahydro[1,2-a]pyrimidin-4-on und 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
AU2002350487C1 (en) * 2001-09-21 2008-10-02 Mitsubishi Pharma Corporation Substituted 2-pyridinyl-6,7,8,9- tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
CN1247586C (zh) * 2001-09-21 2006-03-29 赛诺菲安万特 治疗神经退化性疾病的取代的2－嘧啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮及7－嘧啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1h)酮衍生物
EP1295884A1 (de) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)on Derivate
BR0308109A (pt) * 2002-02-28 2005-01-04 Sanofi Aventis Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila
US7192948B2 (en) * 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors

Also Published As

Publication number Publication date
NZ547956A (en) 2010-03-26
EP1557417A1 (de) 2005-07-27
AU2004299285A1 (en) 2005-06-30
AU2004299285B2 (en) 2010-03-18
CN1914208A (zh) 2007-02-14
DE602004006169D1 (de) 2007-06-06
TWI346664B (en) 2011-08-11
NO20063187L (no) 2006-09-19
PL1699795T3 (pl) 2008-01-31
EP1699795A1 (de) 2006-09-13
WO2005058908A1 (en) 2005-06-30
US7294631B2 (en) 2007-11-13
US20070010539A1 (en) 2007-01-11
IL176287A0 (en) 2006-10-05
CY1107982T1 (el) 2013-09-04
BRPI0417208A (pt) 2007-02-06
ES2286707T3 (es) 2007-12-01
US7547705B2 (en) 2009-06-16
HK1096401A1 (en) 2007-06-01
EP1557417B1 (de) 2007-03-07
MEP21408A (en) 2010-06-10
EA200601192A1 (ru) 2006-10-27
AR047056A1 (es) 2006-01-04
KR20060127055A (ko) 2006-12-11
TW200530247A (en) 2005-09-16
ZA200604960B (en) 2007-11-28
JP4896734B2 (ja) 2012-03-14
DE602004006169T2 (de) 2008-01-10
SI1699795T1 (sl) 2007-10-31
HRP20070328T3 (hr) 2008-03-31
EA010419B1 (ru) 2008-08-29
US20080081820A1 (en) 2008-04-03
CN1914208B (zh) 2010-12-22
PT1699795E (pt) 2007-08-03
MXPA06006931A (es) 2007-04-24
EP1699795B1 (de) 2007-04-25
RS50519B (sr) 2010-05-07
CA2550168A1 (en) 2005-06-30
JP2007514707A (ja) 2007-06-07
DK1699795T3 (da) 2007-09-10

Similar Documents

Publication Publication Date Title
ATE360632T1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
DE50210707D1 (de) Substituierte 2-pyridin-cyclohexan-1,4-diaminderivate
ATE452892T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DK1551802T3 (da) Indol-3-svovlderivater
ATE467631T1 (de) Chinuclidinamidderivate
CY2014041I2 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
ATE438644T1 (de) Chinazolinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
NO20035634L (no) Diamin-derivater
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
ATE319451T1 (de) Tetrahydrochinolin-derivate
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
DE602004021572D1 (de) SUBSTITUIERTE 8-PERFLUORO-6,7,8,9-TETRAHYDROPYRIMIDOi1,2-A PYRIMIDIN-4-ON-DERIVATE
ATE326467T1 (de) Imidazo 1,2-aöpyridine
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1699795

Country of ref document: EP